{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:52Z","timestamp":1792120852261,"version":"4.4.0"},"reference-count":22,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.46989\/001c.124277","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:25:15Z","timestamp":1729679115000},"source":"Crossref","is-referenced-by-count":62,"title":["Overview of approved CAR-T products and utility in clinical practice"],"prefix":"10.46989","volume":"6","author":[{"given":"Shakthi T","family":"Bhaskar","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hmatology and Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N","family":"Savani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hmatology and Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salyka","family":"Sengsayadeth","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine, Hmatology and Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"10299","key":"ref1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"B. D. Shah","year":"2021","journal-title":"The Lancet"},{"issue":"10254","key":"ref2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"J. S. Abramson","year":"2020","journal-title":"The Lancet"},{"issue":"10343","key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"M. Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"8","key":"ref4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"N. C. Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"ref5","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"P. Rodriguez-Otero","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"10297","key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"J. G. Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"J. San-Miguel","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"N. Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"5","key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000416","article-title":"Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 because of CNS Involvement and\/or HIV: A Multicenter Experience","volume":"45","author":"C. A. Yuen","year":"2022","journal-title":"Journal of Immunotherapy"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2216116","article-title":"Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)","volume":"19","author":"K. Kline","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"26","key":"ref11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"S. S. Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.007","article-title":"CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease","author":"U. Ibrahim","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"ref13","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"T. Jain","year":"2023","journal-title":"Blood"},{"key":"ref14","article-title":"FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies","author":"FDA","year":"2023"},{"issue":"7","key":"ref15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMOA2116133\/SUPPL_FILE\/NEJMOA2116133_DATA-SHARING.PDF","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"F. L. Locke","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","volume":"389","author":"J. R. Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"C. A. Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"ref18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"S. L. Maude","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"S. J. Schuster","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"N. H. Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"M. R. Bishop","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"ref22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"M. Wang","year":"2020","journal-title":"New England Journal of Medicine"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/124277-overview-of-approved-car-t-products-and-utility-in-clinical-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:21:36Z","timestamp":1791724896000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/124277-overview-of-approved-car-t-products-and-utility-in-clinical-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.124277","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}